Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00001205 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Natural History of Treated Neurocysticercosis and Long-Term Outcomes

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 391 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor Re-verified, no change to tracked fields
  2. Minor Publications: details revised at 9 of 9 entries
  3. Minor 41 versions Re-verified since May 24, 2025, no change to tracked fieldsv349-v389
  4. Minor Study arms: 1 to 6v348
  5. Minor 6 versions Re-verified since Feb 26, 2025, no change to tracked fieldsv342-v347
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection inside the substance of the brain (parenchymal disease) are seizures and headaches. When the infection is either inside the fluid pockets inside the brain (ventricular disease) or in the space around the brain (subarachnoid disease) patients can have chronic headaches, relapsing aseptic meningitis, hydrocephalus, stroke, and may require neurosurgical intervention. The purpose of this study is to treat patients with anthelmintic therapy (praziquantel and/or albendazole) and anti-inflammatories in alignment with currently accepted best practices and guidelines, depending on the neurocysticercosis subtype. The purpose of the study is to better understand and characterize clinical, biologic, and management factors during treatment that influence long term outcomes. In order to understand this further we collect patient clinical information, patient survey responses, blood, urine samples, and additional cerebral spinal fluid if already being collected for clinical care.
Trial Details
NCT Number NCT00001205
Lead Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Cysticercosis, Neurocysticercosis
Enrollment 500 participants
Start Date
Updated on ClinicalTrials.gov